Cargando…

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B

Establishing an appropriate prophylaxis regimen for children with hemophilia is a critical challenge in developing countries. Barriers including availability and affordability, catheter-related complications, and inhibitor development risks have led to the introduction of new tailored prophylaxis re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eshghi, Peyman, Sadeghi, Elham, Tara, S. Zahra, Habibpanah, Behnaz, Hantooshzadeh, Razieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714659/ https://www.ncbi.nlm.nih.gov/pubmed/28049359 http://dx.doi.org/10.1177/1076029616685429

Ejemplares similares

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
por: Golestani, Mina, et al.
Publicado: (2016)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Management of Severe Hemophilia A: Low-Dose Prophylaxis vs. On-Demand Treatment
por: Munawar Ali, Rabeea, et al.
Publicado: (2023)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A
por: Mizrahi, Terry, et al.
Publicado: (2016)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
por: VALENTINO, L A, et al.
Publicado: (2012)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Haemophilia in the developing countries: the Iranian experience
por: Eshghi, Peyman, et al.
Publicado: (2010)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
por: Gu, Congling, et al.
Publicado: (2022)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
por: Meijón Ortigueira, María del Mar, et al.
Publicado: (2023)

Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen
por: Pareek, Anil, et al.
Publicado: (2020)

Health status and quality of life in patients with severe hemophilia A: A cross-sectional survey
por: Davari, Majid, et al.
Publicado: (2019)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste
por: D’Albini, Lesley, et al.
Publicado: (2023)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer
por: Bertholet, Jenny, et al.
Publicado: (2019)

Molecular pattern of a decrease in the rewarding effect of cocaine after an escalating-dose drug regimen
por: Kołosowska, Karolina, et al.
Publicado: (2022)

Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization
por: Mohammadi, Saeed, et al.
Publicado: (2022)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: a 3-year follow-up study in Senegal, West Africa
por: Touré, Sokhna Aïssatou, et al.
Publicado: (2023)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Hwang, Hyunjung, et al.
Publicado: (2015)

Efficacy of Nuwiq(®) (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
por: Pasi, K John
Publicado: (2021)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Impact of malocclusion severity on oral health-related quality of life in an Iranian young adult population
por: Dalaie, Kazem, et al.
Publicado: (2018)

Immunosuppression Therapy in Acquired Hemophilia A: Pursuing an Optimal Regimen
por: Teixeira Passos, Dúlio, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Single dose cefazolin plus metronidazole versus existing multi-dose regimen for prophylaxis in caesarean section
por: Pore, Shraddha M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gemuctl7tef410klmq3dqfofko